Category - Developments

Developments

Omicron variant underscores need for new COVID vaccine candidates like IBIO-202

iBio (NYSE American:IBIO) updated its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron variant of SARS-CoV-2. According to the WHO, the Omicron variant has at least 30 mutations in...

November 29, 2021

Developments

Tetra Bio-Pharma posts positive initial data from ongoing Phase 2 trials of QIXLEEF

Tetra Bio-Pharma (TSX:TBP; OTCQB:TBPMF; FRA:JAM1) reported positive initial clinical data from its ongoing Phase 2 REBORN 1 and PLENITUDE trials of QIXLEEF for cancer pain. QIXLEEF is a botanical inhaled investigational...

November 29, 2021

Developments

POINT Biopharma licenses Lu-177 production technology from Belgian Nuclear Research Center

POINT Biopharma Global (NASDAQ:PNT) entered into a technology license agreement with the Belgian Nuclear Research Center (SCK CEN) for Lu-177 purification technology to accelerate POINT’s in-house no-carrier-added...

November 24, 2021

Developments

111, Inc. Q3 net revenue climbs 41.6% to RMB 3.35 billion

111, Inc. (NASDAQ:YI), a leading tech-enabled healthcare platform in China, reported that third quarter net revenue rose 41.6% to RMB3.35 billion, or $519.3-milion (U.S.). In a statement, Junling Liu, co-founder...

November 19, 2021

Developments

Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

Oravax Medical, a unit of Oramed Pharmaceuticals (NASDAQ, TASE:ORMP), and Genomma Lab Internacional (BMV:LABB) formed of a 50/50 joint venture to develop and commercialize Oravax’s oral COVID-19 vaccine candidate...

November 18, 2021

Developments

Hepion, FibroFind report positive anti-cancer activity of CRV431 in liver cancer study

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive results of a nonclinical research study showing that CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer. In addition...

November 16, 2021

Developments

iBio, UT Southwestern to investigate IBIO-100 in solid tumors

iBio (NYSEA:IBIO) and the University of Texas Southwestern Medical Center entered into a research collaboration to explore in solid tumors the anti-cancer potential of the molecule that is part of the IBIO-100 program...

November 15, 2021

Developments

Posters on use of Altamira’s RNA delivery platforms presented at AHA scientific sessions

Altamira Therapeutics (NASDAQ:CYTO) announced the presentation of data at the American Heart Association scientific sessions from two studies by a research group at Washington University, St. Louis, on the use of the...

November 15, 2021

Developments

Altamira posts positive Bentrio nasal spray data in Sars-CoV-2 Delta variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for protection...

November 12, 2021

Developments

Anti-cancer mechanism of Hepion’s CRV431 to be featured at liver meeting

Results from a study conducted by Dr. Philippe Gallay’s research group at The Scripps Research Institute examining the anti-tumor mechanism of Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug candidate, CRV431, will be...

November 10, 2021

Category - Developments

Omicron variant underscores need for new COVID vaccine candidates like IBIO-202

Tetra Bio-Pharma posts positive initial data from ongoing Phase 2 trials of QIXLEEF

POINT Biopharma licenses Lu-177 production technology from Belgian Nuclear Research Center

111, Inc. Q3 net revenue climbs 41.6% to RMB 3.35 billion

Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

Hepion, FibroFind report positive anti-cancer activity of CRV431 in liver cancer study

iBio, UT Southwestern to investigate IBIO-100 in solid tumors

Posters on use of Altamira’s RNA delivery platforms presented at AHA scientific sessions

Altamira posts positive Bentrio nasal spray data in Sars-CoV-2 Delta variant

Anti-cancer mechanism of Hepion’s CRV431 to be featured at liver meeting

General

More

Sign up for the BioTuesdays weekly newsletter